The suppression of murine lupus by a tolerogenic peptide involves Foxp3-expressing CD8 cells that are required for the optimal induction and function of Foxp3-expressing CD4 cells

Journal of Immunology

Volumn 181, Issue 5, 2008, Pages 3243-3251

  Sharabi, Amir ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DNA ANTIBODY; DNA MONOCLONAL ANTIBODY; GAMMA INTERFERON; INHIBITOR OF DIFFERENTIATION PROTEIN; INTERLEUKIN 10; MONOCLONAL ANTIBODY; PEPTIDE HCDR1; SYNTHETIC PEPTIDE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; AUTOANTIGEN; CDR1 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; NERVE PROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; FEMALE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL DEPLETION; UPREGULATION; ANIMAL; CELL PROLIFERATION; CYTOLOGY; DISEASE MODEL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; AUTOANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; NERVE TISSUE PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 51549118939     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.5.3243     Document Type: Article

References (40)

1. Hahn, B. H. 2002. An overview of the pathogenesis of systemic lupus erythematosus. In Dubis' Lupus Erythomatosus. D. Wallace and B. H. Hahn, eds. Lippincott Williams & Wilkins, Philadelphia, pp. 87-92.
2. Kono, D. H., and A. N. Theofilopoulos. 2006. Genetics of SLE in mice. Springer Semin. Immunopathol. 28: 83-96.
3. Mendlovic, S., S. Brocke, Y. Shoenfeld, M. Ben Bassat, A. Meshorer, R. Bakimer, and E. Mozes. 1988. Induction of a systemic lupus erythematosuslike disease in mice by a common human anti-DNA idiotype. Proc. Natl. Acad. Sci. USA 85: 2260-2264. (Pubitemid 24315870)
4. Waisman, A., S. Mendlovic, P.-J. Ruiz, H. Zinger, A. Meshorer, and E. Mozes. 1993. The role of the 16/6 idiotype network in the induction and manifestation of systemic lupus erythematosus. Int. Immunol. 5: 1293-1300. (Pubitemid 23308090)
5. Waisman, A., Y. Shoenfeld, M. Blank, P.-J. Ruiz, and E. Mozes. 1995. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int. Immunol. 7: 689-696.
6. Waisman, A., P.-J. Ruiz, E. Israeli, E. Eilat, S. Konen-Waisman, H. Zinger, M. Dayan, and E. Mozes. 1997. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc. Natl. Acad. Sci. USA 94: 4620-4625. (Pubitemid 27194292)
7. Eilat, E., M. Dayan, H. Zinger, and E. Mozes. 2001. The mechanism by which a peptide based on the complementarity determining region-1 of a pathogenic anti-DNA autoantibody ameliorates experimental SLE. Proc. Natl. Acad. Sci. USA 98: 1148-1153.
8. Rapoport, M. J., A. Sharabi, D. Aharoni, O. Bloch, H. Zinger, M. Dayan, and E. Mozes. 2005. Amelioration of SLE-like manifestations in (NZB x NZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin. Immunol. 117: 262-270.
9. Sharabi, A., A. Haviv, H. Zinger, M. Dayan and E. Mozes. 2006. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin. Immunol. 119: 146-155.
10. Sharabi, A., D. Luger, H. Ben-David, M. Dayan, H. Zinger, and E. Mozes. 2007. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J. Immunol. 179: 4979-4987.
11. + cells and TGF-β. Proc. Natl. Acad. Sci. USA 103: 8810-8815.
12. Sharabi, A., H. Azulai, Z. M. Shtoeger, and E. Mozes. 2007. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology 121: 248-257. (Pubitemid 46663093)
13. + T cell responses to glutamic acid decarboxylase 65. Eur. J. Immunol. 37: 78-86.
14. Kumar, V., and E. Sercarz. 2001. An integrative model of regulation centered on recognition of TCR peptide/MHC complexes. Immunol. Rev. 182: 113-121. (Pubitemid 33070212)
15. - regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand. Proc. Natl. Acad. Sci. USA 104: 17459-17464.
16. + T suppressor cell function in patients with active systemic lupus erythematosus. J. Immunol. 166: 6452-6457.
17. + regulatory T cells generated ex vivo with IL-2 and TGF-β suppress a stimulatory graft-versus-host disease with a lupuslike syndrome. J. Immunol. 172: 1531-1539.
18. + T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J. Immunol. 178: 7649-7657.
19. Kang, H. K., M. A. Michaels, B. R. Berner, and S. K. Datta. 2005. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J. Immunol. 174: 3247-3255.
20. Ledbetter, J. A., R. V., Rouse, H. S. Micklem, and L. A. Herzenberg. 1980. T cell subsets defined by expression of Lyt-1,2,3 and Thy-1 antigens: two-parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views. J. Exp. Med. 152: 280-295.
21. Theofilopoulos, A. N. 1995. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol. Today 16: 90-98.
22. + cells to support autoantibody synthesis. Arthritis Rheum. 33: 1216-1225.
23. + T cells from tolerized (New Zealand Black X New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J. Immunol. 173: 3542-3548.
24. Scalapino, K. J., Q. Tang, J. A. Bluestone, M. L. Bonyhadi, and D. I. Daikh. 2006. Suppression of disease in New Zealand Black/New Zealand White lupusprone mice by adoptive transfer of ex vivo expanded regulatory T cells. J. Immunol. 177: 1451-1459.
25. high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 178: 2579-2588.
26. Adachi, Y., M. Inaba, A. Sugihara, M. Koshiji, K. Sugiura, Y. Amoh, S. Mori, T. Kamiya, H. Genba, and S. Ikehara. 1998. Effects of administration of monoclonal antibodies (anti-CD4 or anti-CD8) on the development of autoimmune diseases in (NZW X BXSB)F1 mice. Immunobiology 198: 451-464. (Pubitemid 28098489)
27. Ruiz, P.-J., H. Zinger, and E. Mozes. 1996. Effect of injection of anti-CD4 and anti-CD8 monoclonal antibodies on the development of experimental systemic lupus erythematosus in mice. Cell. Immunol. 167: 30-37.
28. Mendlovic, S., S. Brocke, H. Fricke, Y. Shoenfeld, R. Bakimer, and E. Mozes. 1990. The genetic regulation of the induction of experimental SLE in mice. Immunology 69: 228-236. (Pubitemid 20076491)
29. Singer, D. S., H. Zinger, L. D. Kohn, and E. Mozes. 1999. Differing MHC class I requirements for induction and propagation of experimental systemic lupus erythematosus. Eur. J. Immunol. 29: 2259-2268.
30. Blank, M., M. Ben-Bassat, and Y. Shoenfeld. 1991. Modulation of SLE induction in naive mice by specific T cells with suppressor activity to pathogenic anti-DNA idiotype. Cell. Immunol. 137: 474-486.
31. + dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 196: 1099-1104.
32. Jacob, C. O., P. H. van der Meide, and H. O. McDevitt. 1987. In vivo treatment of (NZB X NZW) F1 lupus-like nephritis with monoclonal antibody to γ interferon. J. Exp. Med. 166: 798-803.
33. Ishida, H., T. Muchamuel, S. Sakaguchi, S. Andrade, S. Menson, and M. Howard. 1994. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179: 305-310. (Pubitemid 24012996)
34. Kumar, V., R. Tabibiazar, H. M. Geysen, and E. Sercarz. 1995. Immunodominant framework region 3 peptide from TCR V β 8.2 chain controls murine experimental autoimmune encephalomyelitis. J. Immunol. 154: 1941-1950.
35. Sela, U., N. Mauermann, R. Hershkoviz, H. Zinger, M. Dayan, L. Cahalon, J. P. Liu, E. Mozes, and O. Lider. 2005. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-β-mediated suppression of LFA-1 and CD44 expression and function. J. Immunol. 175: 7255-7263. (Pubitemid 41713420)
36. Llorente, L., Y. Richaud-Patin, R. Fior, J. Alcocer-Varela, J. Wijdenes, B. M. Fourrier, P. Galanaud, and D. Emilie. 1994. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjógren's syndrome, and systemic lupus erythematosus: a potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum. 37: 1647-1655. (Pubitemid 24985914)
37. Kang, H. K., M. Liu, and S. K. Datta. 2007. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J. Immunol. 178: 7849-7858.
38. Vlad, G., R. Cortesini, and N. Suciu-Foca. 2005. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J. Immunol. 174: 5907-5914. (Pubitemid 40663774)
39. + regulatory T cell subsets. J. Leukocyte Biol. 74: 471-478.
40. Li, M. O., S. Sanjabi, and R. A. Flavell. 2006. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25: 455-471.